With existing customers in Denmark and Italy, this agreement marks an expansion for Qlucore as it secures its first precision diagnostics order in Sweden. The Qlucore goal is to help customers develop analyses that contribute to a more accurate diagnosis, enabling clinicians to make more informed treatment choices.

"Our solutions will facilitate and enable improved diagnostics of cancer; in this case, acute lymphoblastic leukemia (ALL). The goal is to make it easier for the doctor to make a diagnosis and decide how the disease should be treated, and for the patients to receive more precise treatment,” says Carl-Johan Ivarsson, CEO of Qlucore.

Cancer diagnostics are changing rapidly and Qlucore is at the forefront of this development. The Qlucore software, unique in its field, combines advanced visualization, mathematics and biology to make it more quickly and easily accessible to the user.

Qlucore solutions are also available for research and progress towards CE marking is ongoing. The company’s advanced software creates the conditions for faster, better and more accurate cancer diagnostics where the use of AI-based machine learning makes it possible to better categorize patients into more detailed subgroups.